AGP Picks
View all

Florida Health Daily
Provided by AGP

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on May 19, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
May 19, 2026

Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Indeterminate GlobeNewswire
EyePoint Announces Participation at Upcoming Investor Conferences
May 19, 2026

EyePoint Announces Participation at Upcoming Investor Conferences

Indeterminate GlobeNewswire
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026

XORTX Announces Closing of US$5 Million Public Offering

Indeterminate GlobeNewswire
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 19, 2026

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Indeterminate GlobeNewswire
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
May 19, 2026

Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Indeterminate GlobeNewswire
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
May 19, 2026

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

Indeterminate GlobeNewswire
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
May 19, 2026

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Indeterminate GlobeNewswire
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Indeterminate GlobeNewswire
Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
May 19, 2026

Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand

Indeterminate GlobeNewswire
EuroPCR 2026: DynamX® Bioadaptor von Elixir Medical zeigt in der Langzeit-Nachbeobachtung signifikant niedrigere Ereignisraten als ein medikamentenfreisetzender Stent
May 19, 2026

EuroPCR 2026: DynamX® Bioadaptor von Elixir Medical zeigt in der Langzeit-Nachbeobachtung signifikant niedrigere Ereignisraten als ein medikamentenfreisetzender Stent

Indeterminate GlobeNewswire
EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent
May 19, 2026

EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent

Indeterminate GlobeNewswire
El bioadaptador DynamX® de Elixir Medical demuestra tasas de acontecimientos significativamente inferiores a las de los stents liberadores de fármacos
May 19, 2026

El bioadaptador DynamX® de Elixir Medical demuestra tasas de acontecimientos significativamente inferiores a las de los stents liberadores de fármacos

Indeterminate GlobeNewswire
Le Bioadaptateur DynamX® d’Elixir Medical démontre une réduction significative des taux d’événements coronariens par rapport à un stent à élution médicamenteuse
May 19, 2026

Le Bioadaptateur DynamX® d’Elixir Medical démontre une réduction significative des taux d’événements coronariens par rapport à un stent à élution médicamenteuse

Indeterminate GlobeNewswire
EuroPCR 2026: DynamX® Bioadaptor di Elixir Medical mostra tassi di eventi significativamente inferiori rispetto allo stent a rilascio di farmaco
May 19, 2026

EuroPCR 2026: DynamX® Bioadaptor di Elixir Medical mostra tassi di eventi significativamente inferiori rispetto allo stent a rilascio di farmaco

Indeterminate GlobeNewswire
EuroPCR 2026: Bioadaptator DynamX® firmy Elixir Medical wykazuje istotne obniżenie występowania zdarzeń niepożądanych
May 19, 2026

EuroPCR 2026: Bioadaptator DynamX® firmy Elixir Medical wykazuje istotne obniżenie występowania zdarzeń niepożądanych

Indeterminate GlobeNewswire
Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026
May 19, 2026

Avance Clinical to Showcase Oncology Leadership at ASCO Annual Meeting 2026

Indeterminate GlobeNewswire
Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results
May 19, 2026

Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results

Indeterminate GlobeNewswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Indeterminate GlobeNewswire
Clearmind Medicine Announces 1-for-10 Reverse Share Split
May 19, 2026

Clearmind Medicine Announces 1-for-10 Reverse Share Split

Indeterminate GlobeNewswire
GenoSafe advances CLIA pathway for transatlantic ATMP development
May 19, 2026

GenoSafe advances CLIA pathway for transatlantic ATMP development

Indeterminate GlobeNewswire
Show More

Share this page:

Sign up for:

Florida Health Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.